Concepedia

Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies

Wei Peng Yong, Boon Cher Goh, Ross A. Soo, H. C. Toh, Kantharaj Ethirajulu, J M Wood, Veronica Novotny‐Diermayr, S. C. Lee, W.L. Yeo, David Chan,

Annals of Oncology · 2011 · 39 citations · 14 references

DOI

Concepts

References

14

Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer

William Kevin Kelly, Owen A. O’Connor, Lee M. Krug et al. · Journal of Clinical Oncology · 2005 · 907 citations · Full text

, , +16

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies

Francis J. Giles, Thomas Fischer, Jörge E. Cortes et al. · Clinical Cancer Research · 2006 · 314 citations

, , +17

Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589

David Z. Qian, Yukihiko Kato, Shabana Shabbeer et al. · Clinical Cancer Research · 2006 · 272 citations

, , +15

Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer

Suresh S. Ramalingam, Michael L. Maitland, Paul Frankel et al. · Journal of Clinical Oncology · 2009 · 270 citations

, , +16

Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell Lymphoma

Bhupinder Mann, John R. Johnson, Kun He et al. · Clinical Cancer Research · 2007 · 262 citations · Full text

, , +16